Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion in rats

International Journal of Pharmaceutics

Volumn 249, Issue 1-2, 2002, Pages 149-156

  Kim, Soo Jin ^a   Choi, Hoo Kyun ^b   Lee, Yong Bok ^a  

^a Chonnam National University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Cyclosporin A; O W emulsion; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CIPOL; CYCLOSPORIN A; CYCLOSPORIN; SOYBEAN OIL; WATER;

ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BLOOD; BLOOD ANALYSIS; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; EMULSION; IMMUNOASSAY; LYMPHOCYTE SUBPOPULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; CYCLOSPORINE; DRUG EVALUATION, PRECLINICAL; EMULSIONS; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOYBEAN OIL; WATER;

EID: 0037027847     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00490-8     Document Type: Article

References (29)

1. Agarwal R.P., McPherson R.A., Threatte G.A. Assessment of cyclosporin A in whole blood and plasma in five different hematocrits. Ther. Drug Monit. 7:1985;61-65.
2. Awni W.M. Pharmacodynamic monitoring of cyclosporin. Clin. Pharmcokinet. 23:1992;428-448.
3. Berg A.P., Twilhaar W.N., Mesander G., Son W.J., Bij W., Klompmaker I.J., Slooff M.J.H., The T.H., Leij L.H.F.M.L. Quantitation of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation. 65:1998;1066-1071.
4. Bontempo J.A. Development of Biopharmaceutical Parenteral Dosage Forms. 1997;Marcel Dekker, New York.
5. Cavanak T., Sucker H. Formulation of dosage forms. Prog. Alleragy. 38:1986;65-72.
6. Corvari S.J., Hollenbeck R.G., Leslie J., Plaisance K.I., Young D. Absorption and disposition of colloidal drug delivery systems: high-performance liquid chromatographic (HPLC) analysis of a cyclosporin emulsion. Pharm. Res. 8:1991;40-42.
7. Dayneka N.L., Garg V., Jusko W.J. Comparison of four basic models of indirect pharmacodynamic response. J. Pharmacokinet. Biopharm. 21:1993;457-478.
8. Drewe J., Meier R., Vonderscher J., Kiss D., Posanski U., Kissel T., Gyr K. Enhancement of the oral absorption of cyclosporin in men. Br. J. Clin. Pharmacol. 34:1992;60-64.
9. Fahr A., Holz M., Fricker G. Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics. Pharm. Res. 12:1995;1189-7798.
10. Ferron G.M., Jusko W.J. Species- and gender-related differences in cyclosporine-prednisolone-sirolimus interactions in whole blood lymphocyte proliferation assays. J. Pharmacol. Exp. Ther. 286:1998;191-200.
11. Ferron G.M., Pyszczynsk N.A., Jusko W.J. Gender-related assessment of cyclosporine-prednisolone-sirolimus interactions in three human lymphocyte proliferation assays. Transplantation. 65:1998;1203-1209.
12. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Application. second ed. 1997;Swedish Pharmaceutical Press, Stockholm.
13. Gibaldi M., Perrier D. Pharmacokinetics. second ed. 1982;Marcel Dekker, New York.
14. Gijtenbeek J.M.M., Van den Bent M.J., Vecht C.J. Cyclosporine neurotoxicity: a review. J. Neurol. 246:1999;339-346.
15. Gobburu J.V.S., Jusko W.J. Role of dosage regimen in controlling indirect pharmacodynamic response. Adv. Drug Del. Rev. 33:1998;221-223.
16. Kawaguchi-Miyashita M., Nanno M., Shimada S., Nagaoka N., Okada Y., Matsumoto S. A step-wise expansion of intestinal intraepithelial T lymphocytes in association with microbial colonization is defined by sensitivity to cyclosporin A. Immunology. 91:1997;628-634.
17. Maa Y., Hsu C.C. Performance of sonication and microfluidization for liquid-liquid emulsification. Pharm. Dev. Technol. 4:1999;233-240.
18. Malmary M.F., Houti I., Labat C., Batalla A., Moussamih S., Bouguettaya D., Oustrin J., Houin G. Chronopharmacokinetics of cyclosporine A following a single i.v. dose in the Wistar rat. Eur. J. Pharm. Sci. 3:1995;49-56.
19. Miller T.E., Findon G., Ormrod D.J. Suppression of inflammation by cyclosporin A is mediated via a T lymphocyte-independent process. Pharm. Res. 9:1992;1252-1255.
20. Molpeceres J., Chacon M., Guzman M., Aberturas M.R., Berges L. Dependency of cyclosporine tissue distribution and metabolism on the age and gender of rats after a single intravenous dose. Int. J. Pharm. 197:2000;129-141.
21. Noble S., Markham A. Cyclosporin-A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation. Drugs. 50:1995;924-941.
22. Tarr B.D., Yalkowsky S.H. Enhanced intestinal absorption of cyclosporine in rats though the reduction of emulsion droplet size. Pharm. Res. 6:1989;40-43.
23. Tibell A., Norrlind B. Cyclosporin A in fat emulsion carriers: studies on the immunosuppressive potential, using the heterotopic heart transplant model in rats. Trans. Int. 7:1994;438-441.
24. Tibell A., Ringden O., Sundberg B. Cyclosporine A in fat emulsion carrier: immunosuppressive effect in vitro. Scand. J. Immunol. 35:1992;231-236.
25. Tibell A., Larsson M., Alvestrand A. Dissolving intravenous cyclosporin A in a fat emulsion carrier prevents acute renal side effects in the rats. Trans. Int. 6:1993;69-72.
26. Tibell A., Lindholm A., Säwe J., Chen G., Norrlind B. Cyclosporin A in fat emulsion carriers: experimental studies on pharmacokinetics and tissue distribution. Pharmacol. Toxicol. 76:1995;115-121.
27. Vadiei K., Perez-Soler R., Lopez-Berestein G., Luke D.R. Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine. Int. J. Pharm. 57:1989;125-131.
28. Yee G.C., Salomon D.R. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. third ed. 1992;Applied Therapeutics, Vancouver.
29. Zhang Q., Yie G., Li Y., Yang Q., Nagai T. Studies on the cyclosporin A loaded stearic acid nanoparticles. Int. J. Pharm. 200:2000;153-159.